MENU
RGEN
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Repligen (RGEN) Ownership - Who owns Repligen?

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies... Show more

Industry: #Biotechnology

Profile

Industry
Biotechnology
Address
41 Seyon Street
Phone
+1 781 250-0111
Employees
2000
Web
https://www.repligen.com

Details

Group
Domestic Stock Funds
Category
Pharmaceuticals
Capitalization
6.9B
P/E Ratio
134.41
Total Cash
784.53M
Projected Growth
1.93
Total Debt
687.62M
Revenue
763.34M
Risk (Beta)
1.04
Dividend Yield
N/A
Total Cash/Share
13.91
Total Debt/Equity
N/A
Revenue/Share
13.49 USD as % of share price
View a ticker or compare two or three
RGEN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a developer of biologic drugs

Industry PharmaceuticalsOther

Profile
Details
Industry
Biotechnology
Address
41 Seyon Street
Phone
+1 781 250-0111
Employees
2000
Web
https://www.repligen.com